
NYSE:BDX
This summary was created by AI, based on 1 opinions in the last 12 months.
Becton Dickinson (BDX-N) has undergone significant structural changes recently, including the spin-off of its life sciences business, which is now merged with WAT. This strategic shift positions BDX as a dedicated medical technology company, aiming to focus on higher-growth and higher-margin sectors. While the company's previous earnings per share (EPS) target for 2026 was $15, it has now adjusted this figure to $12.50. However, BDX's operating margin expectations have improved significantly, increasing from 21% to 25%. With the stock currently trading at a relatively cheap 14 times earnings, analysts remain cautious but optimistic, indicated by a price target of $200.00, describing the company as a wait-and-see opportunity due to the new risks associated with these changes.
(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.
It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.
Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.